For example, GD55 was developed as a genetically modified oncolytic adenovirus designed for the treatment of hepatocellular carcinoma (HCC) that targets GOLPH2, a Golgi membrane glycoprotein GP73 that is specific for this disease [36]. This evidence concerns the gene GOLM1 and hepatocellular carcinoma.